Skip to main content
. 2019 Apr 19;8(5):1943–1957. doi: 10.1002/cam4.2095

Table 4.

Ongoing phase II clinical trial combining mTOR inhibitors with fulvestrant

Study name (ClinicalTrials.gov identifier) Study arms Study population Outcome measures
NCT02049957 MLN0128(Dual mTORC1/2 Inhibitor) + Fulvestrant Postmenopausal women with HR+/HER2− advanced or metastatic BC that has progressed on treatment with everolimus in combination with exemestane or fulvestrant Percentage of patients experiencing AEs, CBR, ORR, and PFS

AE, adverse event; BC, breast cancer; CBR, clinical benefit rate; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; ORR, overall response rate; PFS, progression‐free survival.